Gossamer Bio, Inc.
Gossamer Bio is a clinical-stage biopharmaceutical company focused on advancing innovative therapies for patients suffering from debilitating diseases. The company has developed the PROSERA Study, a Phase 3 clinical research initiative aimed at evaluating the efficacy and safety of an inhaled investigational product, seralutinib, for treating pulmonary arterial hypertension.
Through the PROSERA Study, Gossamer Bio aims to explore specific biological pathways involved in pulmonary arterial hypertension, seeking to enhance existing treatment options. The study employs a randomized double-blind approach to ensure unbiased evaluation of the drug's effectiveness against a placebo, contributing valuable insights to the field of pulmonary vascular diseases.
Generated from the website